The use of CNIs (CSA or FK) as primary immunosuppressive drugs after pediatric liver
transplantation is one of the main causes of chronic kidney disease in these patients in the
long term.
The study objective is the evaluation of safety of a modification in immunosuppression from a
dual-immunosuppression (CSA or FK plus steroids) to a triple immunosuppression (MMF plus CSA
(reduced dosage) plus steroids.